RT Journal Article
SR Electronic
T1 248 Intrathecal delivery of dendritic cell vaccine eradicates tumor growth and protects against leptomeningeal disease re-inoculation in immunocompetent HER2+ and triple negative breast cancer LMD xenograft models
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP A263
OP A263
DO 10.1136/jitc-2022-SITC2022.0248
VO 10
IS Suppl 2
A1 Law, Vincent
A1 Kodumudi, Krithika
A1 Snyder, Colin
A1 Czerniecki, Brian
A1 Forsyth, Peter
YR 2022
UL http://jitc.bmj.com/content/10/Suppl_2/A263.abstract
AB Background Leptomeningeal disease (LMD) occurs in approx. 5% of patients with breast cancer (BC) with median survival of 2-4 months. Here we investigated intrathecal (IT) delivery of HER2/HER3-dedritic cell vaccine (DCV) in BC-LMD murine model.Methods HER2+ and triple negative breast cancer (TNBC) murine BC cells were injected into CSF of BALB/c mice ro render LMD. We developed an murine Ommaya device that mimics the Ommaya reservoir in patients for the IT administration of DCV into CSF.Results HER2-/HER3-DCV was able to rescue disease mice (71% in HER2+ breast cancer-LMD and 28% in triple negative breast cancer-LMD) with complete tumor regression. Surviving mice also exhibited adaptive immunity against tumor rechallenge.Conclusions Our preclinical data supported a clinical trial (submitted) of the IT delivery of DCV in breast cancer patients with LMD.Ethics Approval For animal use, Institutional Animal Care and Use Committee (IACUC) approval was obtained from the University of South Florida (IS00010398) as well as been reviewed by the Department of Defense Animal Care and Use Review Office.